Výsledky vyhledávání - "Sarah M. Takimoto"

Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Autor: Antonio Jimeno, Aik-Choon Tan, Marileila Varella-Garcia, Barbara A. Frederick, Francois Wilhelm, Dara L. Aisner, Sarah M. Takimoto, Daniel Sehrt, Brian W. Vogler, Gregory N. Gan, Justin Eagles-Soukup, Adrian Umpierrez, Phuong Le, J. Jason Morton, David P. Astling, Magdalena J. Glogowska, Daniel W. Bowles, Stephen B. Keysar, Ryan T. Anderson

PDF file - 64K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e8e7717de4950956e210d0d4a5249dc
https://doi.org/10.1158/1535-7163.22497478

Zobrazit plný text záznamu

Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous cell carci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36906326f4b2438531275d5ad4819da3
https://doi.org/10.1158/1535-7163.c.6535627.v1

Zobrazit plný text záznamu

Supplementary Figures 1 - 9 from Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

PDF file - 1255K, Confirmation of GLI1 modulation by EGFR activation (S1); Epithelial gene expression profile and morphology predicts erlotinib sensitivity in HNSCC cell lines (S2); Zeb1 transcription factor is key driver of EGF induced EMT (S3); EGF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974366581a1d358ebdce703ca2a05791
https://doi.org/10.1158/0008-5472.22397691.v1

Zobrazit plný text záznamu

Supplementary Figure Legend from Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

PDF file - 113K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eed4e61fefdacf8cbcfedd4601c284d
https://doi.org/10.1158/0008-5472.22397694.v1

Zobrazit plný text záznamu

Supplementary Tables 1 - 2 from Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

PDF file - 29K, EGFR dependent EMT quantified as percent Vimentin-positive cells in culture (S1); Combination therapy delays or blocks tumor re-growth in sensitive xenografts (S2).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f5d776b371154deba8c0b472f98116
https://doi.org/10.1158/0008-5472.22397688

Zobrazit plný text záznamu

Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

Publikováno v: Cancer Research. 73:3381-3392

The EGF receptor (EGFR)-directed monoclonal antibody cetuximab is the only targeted therapy approved for the treatment of squamous cell carcinoma of the head and neck (HNSCC) but is only effective in a minority of patients. Epithelial-to-mesenchymal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8185652e9e3d11d0876b4304c46be8e4
https://doi.org/10.1158/0008-5472.can-12-4047

Zobrazit plný text záznamu

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Publikováno v: Molecular Oncology. 7:776-790

Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f6a2e108308f820a193b69aef1e143
https://doi.org/10.1016/j.molonc.2013.03.004

Zobrazit plný text záznamu

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas

Autor: Justin R. Eagles-Soukup, Stephen B. Keysar, Aik Choon Tan, Marileila Varella-Garcia, Sarah M. Takimoto, Phuong Le, Daniel W. Bowles, Antonio Jimeno, Brian W. Vogler, John Morton, Barbara Frederick, Francois Wilhelm, Magdalena J. Glogowska, Dara L. Aisner, Gregory N. Gan, Ryan T. Anderson, Adrian Umpierrez, Daniel Sehrt, David P. Astling

Publikováno v: Molecular cancer therapeutics. 12(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05aedbbf9f1bab9683e3abcea403f7e2
https://pubmed.ncbi.nlm.nih.gov/23873848

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání